COVID-19 vaccine documents unlawfully accessed in EMA cyberattack: Moderna

Published On 2020-12-15 08:03 GMT   |   Update On 2020-12-15 12:29 GMT

New Delhi: Moderna Inc said on Monday it was informed by the European Medicines Agency (EMA) certain documents related to pre-submission talks of its Covid-19 vaccine candidate were unlawfully accessed in a cyberattack on the medicines regulator.

The EMA, which assesses medicines and vaccines for the European Union, said earlier this month that it had been targeted in a cyberattack, which also gave hackers access to documents related to the development of Pfizer Inc and BioNTech Covid-19 vaccine.
Moderna said its submission to the EMA did not include any information identifying individual study participants and there is no information at present that any participants had been identified in any way.

Read also: Covid-19 development documents unlawfully accessed in cyberattack: Pfizer, BioNTech



Tags:    
Article Source : Reuters

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News